All In Biotech

Drug Trial Radar · NCT05203510

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

A Phase 4, Prospective, Multicenter, Single-Arm Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Patients With Pulmonary Arterial Hypertension: ARTISAN (Afterload Reduction To Improve Right Ventricular Structure And FuNction)

Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

52

Actual

Start

Oct 20, 2022

Primary completion

Apr 30, 2026

Study completion Apr 30, 2028

Sponsor

Lead sponsor
United TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Lung Biotechnology PBC
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • Parenteral TreprostinilDrug

    Parenteral treprostinil will be administered per schedule specified in the arm description.

  • Oral TreprostinilDrug

    Oral treprostinil will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Right Ventricular Ejection Fraction (RVEF), as Measured by Cardiac Magnetic Resonance Imaging (cMRI) at Month 12Time frame: Baseline, Month 12

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center (University of Arizona)

    Phoenix, Arizona

  • HonorHealth John C. Lincoln Medical Center

    Phoenix, Arizona

  • University of California San Francisco - Fresno

    Fresno, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California Davis Medical Center

    Sacramento, California

  • University of California San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine

    San Francisco, California

  • Hartford Hospital

    Hartford, Connecticut

  • USF

    Tampa, Florida

  • Georgia Clinical Research

    Austell, Georgia

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Indiana University Health North Hospital

    Indianapolis, Indiana

  • Community Health Network

    Indianapolis, Indiana

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Morristown Medical Center

    Morristown, New Jersey

  • University of Rochester Medical Center

    Rochester, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Integris Baptist Medical Center

    Oklahoma City, Oklahoma

  • Oklahoma Heart Institute

    Tulsa, Oklahoma

  • Temple Hospital

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Prisma Health

    Greenville, South Carolina

  • UT Southwestern Medical Center

    Dallas, Texas

  • Carilion Clinic

    Roanoke, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.